Literature DB >> 27926718

Getting stem cell patients 'on the grid'.

Paul Wicks1, Jamie Heywood1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27926718     DOI： 10.1038/nbt.3740

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  13 in total

1.  Human intrathecal transplantation of peripheral blood stem cells in amyotrophic lateral sclerosis.

Authors:  C G Janson; T M Ramesh; M J During; P Leone; J Heywood
Journal:  J Hematother Stem Cell Res       Date:  2001-12

2.  Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm.

Authors:  Paul Wicks; Timothy E Vaughan; Michael P Massagli; James Heywood
Journal:  Nat Biotechnol       Date:  2011-04-24       Impact factor: 54.908

3.  No benefits from experimental treatment with olfactory ensheathing cells in patients with ALS.

Authors:  Sanne Piepers; Leonard H van den Berg
Journal:  Amyotroph Lateral Scler       Date:  2010-05-03

4.  Transplantation of spinal cord-derived neural stem cells for ALS: Analysis of phase 1 and 2 trials.

Authors:  Jonathan D Glass; Vicki S Hertzberg; Nicholas M Boulis; Jonathan Riley; Thais Federici; Meraida Polak; Jane Bordeau; Christina Fournier; Karl Johe; Tom Hazel; Merit Cudkowicz; Nazem Atassi; Lawrence F Borges; Seward B Rutkove; Jayna Duell; Parag G Patil; Stephen A Goutman; Eva L Feldman
Journal:  Neurology       Date:  2016-06-29       Impact factor: 9.910

5.  Clinical trials: what a waste.

Authors:  John P A Ioannidis
Journal:  BMJ       Date:  2014-12-10

Review 6.  ALSUntangled: introducing The Table of Evidence.

Authors: 
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-12-27       Impact factor: 4.092

7.  The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

Authors:  J M Cedarbaum; N Stambler; E Malta; C Fuller; D Hilt; B Thurmond; A Nakanishi
Journal:  J Neurol Sci       Date:  1999-10-31       Impact factor: 3.181

8.  Phase I clinical trial of safety of L-serine for ALS patients.

Authors:  Todd D Levine; Robert G Miller; Walter G Bradley; Dan H Moore; David S Saperstein; Lynne E Flynn; Jonathan S Katz; Dallas A Forshew; James S Metcalf; Sandra A Banack; Paul A Cox
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2016-09-02       Impact factor: 4.092

9.  Off the grid.

Authors: 
Journal:  Nat Biotechnol       Date:  2016-09-08       Impact factor: 54.908

10.  How common are ALS plateaus and reversals?

Authors:  Richard S Bedlack; Timothy Vaughan; Paul Wicks; Jamie Heywood; Ervin Sinani; Roger Selsov; Eric A Macklin; David Schoenfeld; Merit Cudkowicz; Alex Sherman
Journal:  Neurology       Date:  2015-12-09       Impact factor: 9.910
View more
  2 in total

Review 1.  A blueprint for the next generation of ELSI research, training, and outreach in regenerative medicine.

Authors:  Judy Illes; Douglas Sipp; Erika Kleiderman; Shelly Benjaminy; Rosario Isasi; Geoff Lomax; Zubin Master; Jennifer McCormick; Ubaka Ogbogu; Vardit Ravitsky; Julie M Robillard; Fabio Rossi; Brenda Wilson; Amy Zarzeczny
Journal:  NPJ Regen Med       Date:  2017-07-05

Review 2.  Can civil lawsuits stem the tide of direct-to-consumer marketing of unproven stem cell interventions.

Authors:  Claire Horner; Evelyn Tenenbaum; Douglas Sipp; Zubin Master
Journal:  NPJ Regen Med       Date:  2018-02-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.